Zacks Investment Research downgraded Pacific Biosciences of California (NASDAQ:PACB) to Sell in a statement released earlier today.
- Updated: October 9, 2016
Yesterday Pacific Biosciences of California (NASDAQ:PACB) traded -1.55% lower at $9.02. PACB’s 50-day average is $8.71 and its two hundred day average is $8.73. The last stock price is up 1.62% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 684,924 shares of PACB traded hands, down from an avg. volume of 1,148,030
Zacks Investment Research has downgraded Pacific Biosciences of California (NASDAQ:PACB) to Sell in a report released on 10/5/2016.
Recent Performance Chart
Pacific Biosciences of California has 52 week low of $6.76 and a 52 week high of $14.00 and has a market cap of $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 6 brokerages have issued a research note on the company. The average stock price target is $12.50 with 3 brokerages rating the stock a strong buy, 1 firm rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company's Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Based on the Company's SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.